ASCO President Presses Medicare to Cover Costs of Cancer Clinical Trial Participants

Publication
Article
OncologyONCOLOGY Vol 13 No 5
Volume 13
Issue 5

Allen Lichter, MD, president of the American Society of Clinical Oncology (ASCO), stated at a meeting sponsored by the

Allen Lichter, MD, president of the American Society of Clinical Oncology (ASCO), stated at a meeting sponsored by the Institute of Medicine (IOM) that Medicare should pay routine patient costs for people who participate in qualified clinical trials of cancer treatments. The issue of reimbursement for clinical trial participants has been controversial for years, of course. Sens. Connie Mack (R-FL) and Jay Rockefeller (D-W. Va.) were scheduled to reintroduce their clinical trials bill in April. It creates a small “demonstration program”.

The IOM, which is part of the National Academy of Sciences, will make a report on clinical trials reimbursement to the Health Care Financing Administration by September 30. “It is ASCO’s view that Medicare beneficiaries who have paid premiums and taxes should be entitled to expect coverage of their hospital and physician costs and routine diagnostic tests that would be administered regardless of whether the patient was enrolled in a trial,” Lichter said at the IOM meeting.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content